|Min SIP Amount||₹100|
|NAV||₹255.49 (25 Jan 2021)|
|Fund Started||05 Jun 2004|
|Fund Size||₹4,383 Cr|
|Sun Pharmaceutical Inds. Ltd.||Healthcare||Equity||10.8%|
|Aurobindo Pharma Ltd.||Healthcare||Equity||10.5%|
|Divi's Laboratories Ltd.||Healthcare||Equity||9.2%|
|Dr. Reddy's Laboratories Ltd.||Healthcare||Equity||8.9%|
|Cadila Healthcare Ltd.||Healthcare||Equity||6.5%|
|Fortis Healthcare (India) Ltd||Healthcare||Equity||5.7%|
|Gland Pharma Ltd.||Healthcare||Equity||4.3%|
|Thyrocare Technologies Ltd.||Healthcare||Equity||4.3%|
Nippon India Pharma Fund Growth is a Equity Mutual Fund Scheme launched by Nippon India Mutual Fund. This scheme was made available to investors on 05 Jun 2004. Sailesh Raj Bhan is the Current Fund Manager of Nippon India Pharma Fund Growth fund.The fund currently has an Asset Under Management(AUM) of ₹4,383 Cr and the Latest NAV as of 25 Jan 2021 is ₹255.49.
The Nippon India Pharma Fund Growth is rated High risk. Minimum SIP Investment is set to 100. Minimum Lumpsum Investment is 5000. Exit load of 1% if redeemed within 1 month.
The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies.
Returns are taxed at 15%, if you redeem before one year. After 1 year, you are required to pay LTCG tax of 10% on returns of Rs 1 lakh+ in a financial year.